Abstract
Introduction: Soft tissue sarcomas are a rare and heterogeneous group of tumors. They are derived from connective tissue and comprise less than one percent of all malignancies. Currently the primary treatment approach is surgical resection optionally accompanied by radio- and chemotherapy. However the response rate of sarcomas towards chemotherapeutics is still unsatisfying. The innate immune response might play a key role in cancer development and might therefore offer a more effective option for the treatment of this cancer entity. The goal of this in vitro and in vivo study was to analyse the oncolytic effect of a novel host defense–like lytic peptide in human sarcoma cell lines. Methods and Materials: In vitro a human lipo- (SW872) and synovialsarcoma (SW982) cell line, and primary human fibroblasts were exposed to [D]-K3H3L9, a short 15-mer D,L-amino acid peptide (exposure time: 24 hours, dose: 0 μM to 100 μM). Morphological changes were controlled microscopically. Cell vitality (MTT-assay) and proliferation (BrdU-assay) were quantified and the LD50 was determined. In vivo SW872 and SW982 cells (5 × 106 cells/mouse) were injected subcutaneously into athymic nude mice. When the mean tumor volume reached 216 mm3 (SW872) or 138 mm3 (SW982), the peptide was administered intratumorally 3 times per week (single dose: 8.5 mg/kg) for 3 weeks with one subsequent follow-up week. Histological and immunohistochemical analyses were performed afterwards. Results: In vitro [D]-K3H3L9 significantly (p < 0.05) inhibited cell metabolism in a dose dependent manner. The mean LD50 was reached at a peptide concentration of 52 μM (SW872) and 24 μM (SW982). Microscopic findings confirmed these results. In comparison to the control group the tumor volume of the treatment group significantly decreased. In the SW872 tumors a complete remission could be shown macroscopically in 43 % of cases. The histological and immunohistochemical analysis demonstrated a significant decrease of proliferation and an increase of the necrotic area in the treatment group. Conclusion: In summary, [D]-K3H3L9 exerts very promising potent oncolytic activity on lipo- and synovialsarcoma cells in vitro and in vivo. Thus HDPs may offer a novel therapeutic option in the treatment of soft tissue sarcomas.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Fletcher CDM et al. (2002) Soft tissue tumours: Epidemiology, clinical features, histopathological typing and grading; World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon IARC Press 12–18
Steinstraesser L et al. (2009) Expression Profile of Human Beta-Defensin 3 in Oral Squamous Cell Carcinoma. Cancer Invest Eupub ahead
Papo N, Shai Y (2005) Host Defense Peptides as New Weapons in Cancer Treatment. CMLS, Cell Mol Life Sci 62: 784–790
Lehmann J et al. (2006) Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. Eur Urol 50: 141–147
Papo N et al. (2004) Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res 64: 5779–5786Chaoter 42
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schubert, C. et al. (2010). Designer Host Defense Peptide als neue Therapieoption bei Weichgewebssarkomen?. In: Gradinger, R., Menger, M., Meyer, HJ. (eds) Chirurgisches Forum und DGAV Forum 2010. Deutsche Gesellschaft für Chirurgie, vol 39. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12192-0_42
Download citation
DOI: https://doi.org/10.1007/978-3-642-12192-0_42
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12191-3
Online ISBN: 978-3-642-12192-0
eBook Packages: Medicine (German Language)